Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 <scp>SYMPATICO</scp> study

Wang, Michael;Jurczak, Wojciech;Trneny, Marek;Belada, David;Tam, Constantine;et.al.
(2026) British Journal of Haematology — Vol. 209, n° 2, p. 734-739 (2026)

Files

Wang M, Br J Haematol, 2026.pdf
  • Open Access
  • Adobe PDF
  • 439.28 KB

Details

Authors
  • Wang, Michaelorcid-logoDepartment of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston Texas USA
    Author
  • Jurczak, WojciechDepartment of Clinical Oncology Maria Skłodowska‐Curie National Research Institute of Oncology Kraków Poland
    Author
  • Trneny, Marekorcid-logoFirst Department of Internal Medicine – Hematology General University Hospital in Prague Prague Czech Republic
    Author
  • Belada, David4th Department of Internal Medicine – Haematology Charles University, Hospital and Faculty of Medicine Hradec Králové Czech Republic
    Author
  • André, MarcUCLouvain
    Author
  • Tam, Constantineorcid-logoPeter MacCallum Cancer Centre Alfred Health and Monash University Melbourne Victoria Australia
    Author
Show more
Affiliations

Citations

Wang, M., Jurczak, W., Trneny, M., Belada, D., Wrobel, T., Ghosh, N., Keating, M.-m., Van Meerten, T., Alvarez, R., Von Keudell, G., Thieblemont, C., Peyrade, F., André, M., Hoffmann, M., Szafer‐glusman, E., Lin, J., Dean, J., Neuenburg, J., & Tam, C. (2026). Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 <scp>SYMPATICO</scp> study. British Journal of Haematology, 209(2), 734-739. https://doi.org/10.1111/bjh.70620 (Original work published 2026)